{"prompt": "['Demographic data will include age, sex, and self-reported race and ethnicity.', '4.5.3', 'Physical Examinations', 'A complete physical examination be performed during Screening and should include, but not', 'necessarily be limited to, an evaluation of the head, eyes, ears, nose, and throat and the', 'cardiovascular, dermatological, musculoskeletal, respiratory, gastrointestinal, and', 'neurological systems. Any abnormality identified during screening should be recorded on the', 'General Medical History and Baseline Conditions eCRF. Targeted physical examinations (i.e.,', 'joints for bleeds and evidence of arthropathy; skin for bruises, hematomas and ISRs; other organ', 'systems as clinically indicated) should be conducted at subsequent visits or as clinically indicated.', 'New or worsened clinically significant abnormalities from screening should be recorded as', 'adverse events, if appropriate, on the Adverse Event eCRF.', '4.5.4', 'Vital Signs', 'Vital signs will include measurement of body temperature (oral, rectal, axillary, or tympanic),', 'heart and respiratory rates, blood pressure and weight, and should be measured. On', 'treatment days, measurement should occur prior to emicizumab administration. Height will be only', 'measured at selected visits. Additional vital sign assessments may also be taken anytime as', 'unscheduled assessments as judged by the investigator. In addition, vital signs may be', 'taken to help monitor for hypersensitivity reactions during or after injections at the', \"investigator's discretion, although these data should not be entered into the eCRF.\", '4.5.5', 'Concomitant Medications', 'The definition of concomitant medications, as well as permitted and prohibited medications is', 'described in Section 4.4. Concomitant medications used by a patient from 4 weeks prior to initiation', 'of emicizumab to the Study Completion/Early Termination Visit (or the Safety Follow-up Visit, if', 'applicable) should be reported to the investigator and recorded on the Concomitant Medications eCRF.', 'Any hemostatic medications (e.g. bypassing agents) and other medications used to treat or prevent', 'bleeds in the 6-month period prior to starting emicizumab treatment will also be collected. Treatments', 'for bleeds (i.e., bypassing agents and other medications to treat bleeds), will be collected in the bleed', 'records.', '4.5.6', 'Laboratory, Biomarker, and Other Biological Samples', 'Central laboratory assessments will be performed as indicated (see Table 9). Unless otherwise', \"specified, additional analysis may be performed at a local laboratory, as per the investigator's\", \"discretion. Any additional laboratory results which are required as part of the patient's safety\", 'assessment should be recorded in the unscheduled visit eCRFs. Central labs are part of the non-eCRF', 'data which will be sent to the Sponsor directly by the central lab vendor.', 'On treatment days, blood collection should occur within 2 hours prior to emicizumab', 'administration unless otherwise specified.', 'Table 10', 'Central vs Local Laboratory Assessments', 'Sample', 'Laboratory', 'Emicizumab - F. Hoffmann-La Roche Ltd', '117 / Protocol MO39129, Version 3']['Sample', 'Laboratory', 'Hematology and blood chemistry', 'Central', 'Pregnancy tests', 'Local', 'HIV and hepatitis serology', 'Local', 'Anti-FVIII antibodies', 'Central', 'Anti-emicizumab antibodies', 'Central', 'Pharmacokinetic samples', 'Central', 'Safety biomarkers', 'Central', 'Safety coagulation system biomarkers', 'Central', 'PD biomarkers', 'Central', 'Bone and joint biomarkers', 'Central', 'Extra testing with use of bypass agents', 'Central', '4.5.6.1', 'Hematology and Blood Chemistry', 'Hematology and blood chemistry tests include:', 'Hematology (hemoglobin, hematocrit, platelet count, red blood cell [RBC] count, white', 'blood cell [WBC] count, absolute or non-absolute differential count [neutrophils,', 'eosinophils, lymphocytes, monocytes, basophils, and other cells], mean corpuscular', 'volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration,', 'RBC distribution width, prothrombin time [PT] in seconds, and international normalized', 'ratio [INR; the PT/INR ratio will be calculated])', 'Serum chemistry (sodium, potassium, chloride, glucose, blood urea nitrogen (BUN),', 'creatinine, calcium, phosphorus, magnesium, total and direct bilirubin, total protein,', 'albumin, ALT, AST, lactate dehydrogenase (LDH), alkaline phosphatase, and creatine', 'phosphokinase)', 'Laboratory assessments completed during Screening do not have to be repeated at Week 1, if the', \"period between Screening and Week 1 is < 5 days and there has been no change in the patient's health\", 'status as assessed by the investigator.', 'Samples will be sent to the central laboratory for analysis.', '4.5.6.2', 'Pregnancy Tests', 'Female patients of childbearing potential (including those who have had a tubal ligation) will be', 'required to have a negative serum pregnancy test result during Screening, and again within 7 days', 'prior to the first dose of emicizumab. Urine pregnancy tests will be performed throughout the study', 'treatment period. Pregnancy testing will be conducted at the local laboratory.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '118 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}